EMAIL THIS PAGE TO A FRIEND

Journal of gastroenterology

Role of pancreatic trypsin in chronic esophagitis induced by gastroduodenal reflux in rats.


PMID 16699853

Abstract

Reflux of the duodenal contents with gastric acid has been reported to contribute to the development of esophageal mucosal damage and inflammation. Recent studies show that pancreatic trypsin can stimulate the production of inflammatory mediators, including chemokines and prostaglandins from human esophageal epithelial cells in vitro. The aim of the present study was to investigate the role of pancreatic trypsin in the pathogenesis of chronic esophageal inflammation induced by gastroduodenal reflux in rats. Esophagogastroduodenal anastomosis was carried out in male Wistar rats by anastomosing the jejunum to the gastroesophageal junction under diethyl ether inhalation anesthesia. The animals undergoing surgery were treated with the control diet, rabeprazole sodium, nizatidine, ecabet sodium, camostat mesilate (CMM), ONO-1714, a specific inducible nitric oxide synthase (iNOS) inhibitor, or meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor. Esophageal injury was evaluated by macroscopic and microscopic findings, and mRNA expression for CINC-1, COX-2, and iNOS was determined by real-time polymerase chain reaction (PCR). Trypsin activity within the esophageal lumen was measured 2 weeks after surgery, and the expression of protease-activated receptor (PAR)-1 and -2 was confirmed by reverse transcription (RT)-PCR. At 8 weeks after surgery, gastroduodenal reflux induced esophageal erosions and ulcer formation as well as marked thickening of the esophageal wall. Histological study showed an increase of thickness of the esophageal mucosa, hyperplasia of the epidermis and basal cells, ulcer formation, and marked infiltration of inflammatory cells. The macroscopic ulcer score and histological ulcer length were significantly reduced by treatment with rabeprazole or CMM but not by nizatidine or ecabet sodium, compared with each control. Rabeprazole, nizatidine, or ecabet sodium did not affect the severity of mucosal hyperplastic scores or histological parameters in esophagitis. In contrast, the CMM group showed a significant decrease in the mucosal hyperplastic and inflammatory scores. The enhanced expression of CINC-1, COX-2, and iNOS mRNA in the control group was also markedly inhibited in the CMM-treated group. ONO-1714 or meloxicam treatment significantly reduced the macroscopic scores of ulcer and hyperplasia. The trypsin activity in the esophageal lumen was significantly increased in the control diet group, and this increase was significantly inhibited in the CMM-treated group. The expression of PAR-1 and -2 mRNA was confirmed in rat esophageal epithelium. With this model, we have demonstrated that CMM significantly reduces inflammation and hyperplasia in the esophageal mucosa. These results indicate that trypsin, which is primarily inhibited by CMM, plays an important role in the mucosal damage induced by gastroduodenal reflux and that it can be a therapeutic target in patients with gastroduodenal reflux esophagitis.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

T1005
Trypsin from bovine pancreas, Type XI, lyophilized powder, ≥6,000 BAEE units/mg protein
T8658
Trypsin from bovine pancreas, suitable for protein sequencing, lyophilized powder
T7309
Trypsin from bovine pancreas, ≥2,500 USP units/mg solid, meets USP testing specifications
T9935
Trypsin from bovine pancreas, essentially salt-free, lyophilized powder, ≥9,000 BAEE units/mg protein, BioReagent, suitable for cell culture
T9201
Trypsin from bovine pancreas, powder, ≥7,500 BAEE units/mg solid
T6424 Trypsin from human pancreas, salt-free, lyophilized powder, vial of ≥1,000 BAEE units
T7409 Trypsin from porcine pancreas, lyophilized powder, Type II-S, 1,000-2,000 units/mg dry solid
T5266 Trypsin from porcine pancreas, lyophilized powder, γ-irradiated, BioXtra, suitable for cell culture, 1,000-2,000 BAEE units/mg solid
T7168 Trypsin from porcine pancreas, tablet, 1 mg tablet
93614 Trypsin from porcine pancreas, ≥10000 U/mg
93615 Trypsin from porcine pancreas, ~1500 U/mg
85450C Trypsin Powder, Porcine 1:250, Gamma irradiated by SER-TAIN Process, dry powder
59427C Trypsin Solution 10X
T4549 Trypsin solution from porcine pancreas, 10 ×, sterile-filtered, BioReagent, suitable for cell culture, 25 g porcine trypsin per liter in 0.9% sodium chloride
T4674 Trypsin solution from porcine pancreas, 10 ×, sterile-filtered, BioReagent, suitable for cell culture, 25 g porcine trypsin per liter in Hanks′ Balanced Salt Solution with phenol red
T4424 Trypsin solution from porcine pancreas, 1 ×, sterile-filtered, BioReagent, suitable for cell culture, 2.5 g porcine trypsin per liter in Hanks′ Balanced Salt Solution with phenol red
59418C Trypsin-EDTA Solution 10X
T3568 TrypZean® bovine, recombinant, expressed in corn, lyophilized powder, ≥3,350 units/mg solid (USP)